Literature DB >> 11402087

Practical guidelines for the use of NESP in treating renal anaemia.

P Aljama, J Bommer, B Canaud, F Carrera, K U Eckardt, W H Hörl, R T Krediet, F Locatelli, I C Macdougall, B Wikström.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11402087     DOI： 10.1093/ndt/16.suppl_3.22

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN： 0931-0509            Impact factor:   5.992


× No keyword cloud information.
  11 in total

Review 1.  Darbepoetin alfa.

Authors:  T Ibbotson; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Association between anemia and mortality in hemodialysis patients is modified by the presence of diabetes.

Authors:  Yukio Maruyama; Eiichiro Kanda; Kan Kikuchi; Masanori Abe; Ikuto Masakane; Takashi Yokoo; Kosaku Nitta
Journal:  J Nephrol       Date:  2021-02-08       Impact factor: 3.902

3.  Intravenously administered darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in patients on hemodialysis.

Authors:  Hiroshi Nagaya; Daijo Inaguma; Akimitsu Kitagawa; Minako Murata; Yutaka Kamimura; Kyoko Hamaguchi; Miho Tatematsu; Sachiyo Suzuki; Kei Kurata; Yukio Yuzawa; Seiichi Matsuo
Journal:  Clin Exp Nephrol       Date:  2009-12-05       Impact factor: 2.801

Review 4.  Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease.

Authors:  Robert Deicher; Walter H Hörl
Journal:  Drugs       Date:  2004       Impact factor: 9.546

5.  A Safe and Easy Introduction of Darbepoetin-Alpha in Patients Receiving Maintenance Hemodialysis and Epoetin Monotherapy: A "Half-and-Half" Combination Therapy.

Authors:  Kazumasa Shimamatsu; Hiroko Inamasu
Journal:  Curr Ther Res Clin Exp       Date:  2013-06

6.  Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability.

Authors:  Javier Arrieta; Iñigo Moina; José Molina; Isabel Gallardo; María Luisa Muñiz; Carmen Robledo; Oscar García; Fernando Vidaur; Rosa Inés Muñoz; Izaskun Iribar; Román Aguirre; Antonio Maza
Journal:  Int J Nephrol Renovasc Dis       Date:  2014-10-09

7.  Administration of a High-Dose Erythropoietin-Stimulating Agent in Hemodialysis Patients is Associated with Late Arteriovenous Fistula Failure.

Authors:  Hye Yun Jeong; Eun Jung Ko; Sang Hoon Kim; Mi Jung Lee; Hye Jeong Cho; Dong Ho Yang; So Young Lee
Journal:  Yonsei Med J       Date:  2017-07       Impact factor: 2.759

8.  Obesity may be erythropoietin dose-saving in hemodialysis patients.

Authors:  Ghada M El-Kannishy; Abir F Megahed; Mona M Tawfik; Ghada El-Said; Rabab T Zakaria; Nahed A Mohamed; Eman M Taha; Alzhraa A Ammar; Abeer M Abd Eltawab; Nagy A Sayed-Ahmed
Journal:  Kidney Res Clin Pract       Date:  2018-06-30

9.  Association between carnitine deficiency and the erythropoietin resistance index in patients undergoing peritoneal dialysis: a cross-sectional observational study.

Authors:  Shohei Kaneko; Keiji Hirai; Junki Morino; Saori Minato; Katsunori Yanai; Yuko Mutsuyoshi; Hiroki Ishii; Momoko Matsuyama; Taisuke Kitano; Mitsutoshi Shindo; Akinori Aomatsu; Haruhisa Miyazawa; Yuichiro Ueda; Kiyonori Ito; Susumu Ookawara; Yoshiyuki Morishita
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

10.  Risk factors for infection and mortality among hemodialysis patients during COVID-19 pandemic.

Authors:  Özgür Can; Gunal Bilek; Sibel Sahan
Journal:  Int Urol Nephrol       Date:  2021-07-05       Impact factor: 2.266
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.